BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 28143735)

  • 1. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
    Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
    J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
    Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
    J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.
    Li Y; Zheng J; Shen Y; Li W; Liu M; Wang J; Zhu S; Wu M
    Med Sci Monit; 2018 May; 24():3293-3300. PubMed ID: 29777582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
    Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
    Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.
    Ye X; Qi J; Wu Y; Yu D; Xu P; Li S; Zhu S; Wu Q; Ren G; Li D
    Diabetes Metab; 2015 Feb; 41(1):82-90. PubMed ID: 25451186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
    Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Miyoshi A; Kondo T; Tsuchida K; Atsumi T; Manda N; Kurihara Y; Aoki S;
    PLoS One; 2015; 10(8):e0135854. PubMed ID: 26284918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice.
    Ye X; Qi J; Ren G; Xu P; Wu Y; Zhu S; Yu D; Li S; Wu Q; Muhi RL; Li D
    Endocrine; 2015 Aug; 49(3):683-92. PubMed ID: 25557015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.
    Liu J; Yang K; Yang J; Xiao W; Le Y; Yu F; Gu L; Lang S; Tian Q; Jin T; Wei R; Hong T
    EBioMedicine; 2019 Mar; 41():73-84. PubMed ID: 30827929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
    Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
    Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin sensitizes FGF21 in glucose and lipid metabolisms via activating common AKT pathway.
    Yu D; Ye X; Wu Q; Li S; Yang Y; He J; Liu Y; Zhang X; Yuan Q; Liu M; Li D; Ren G
    Endocrine; 2016 Jun; 52(3):527-40. PubMed ID: 26607153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
    Ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Drent ML; Diamant M; IJzerman RG
    Diabetes Care; 2016 Feb; 39(2):214-21. PubMed ID: 26283736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans.
    Kyohara M; Shirakawa J; Okuyama T; Kimura A; Togashi Y; Tajima K; Hirano H; Terauchi Y
    Endocrinology; 2017 Dec; 158(12):4152-4164. PubMed ID: 29028997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity.
    Liang Y; Li Z; Liang S; Li Y; Yang L; Lu M; Gu HF; Xia N
    Nutr Diabetes; 2016 Jan; 6(1):e191. PubMed ID: 26807509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a combination of high and low dosage of PEGylated FGF-21 in treatment of diabetes in db/db mice.
    Xu P; Zhang Y; Song L; Khoso MH; Li J; Jiang X; He J; Li J; Ma X; Ren G; Li D
    Biomed Pharmacother; 2016 Dec; 84():97-105. PubMed ID: 27643551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.
    Wu YR; Shi XY; Ma CY; Zhang Y; Xu RX; Li JJ
    Cardiovasc Diabetol; 2019 Nov; 18(1):146. PubMed ID: 31706303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
    Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
    Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
    Takeishi S; Tsuboi H; Takekoshi S
    Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glargine Insulin Use Versus Continuous Regular Insulin in Diabetic Surgical Noncritically Ill Patients Receiving Parenteral Nutrition: Randomized Controlled Study.
    Hakeam HA; Mulia HA; Azzam A; Amin T
    JPEN J Parenter Enteral Nutr; 2017 Sep; 41(7):1110-1118. PubMed ID: 27091835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide improves hepatic insulin resistance via the canonical Wnt signaling pathway.
    Qin Y; Chen M; Yang Y; Zhou XR; Shao SY; Wang DW; Yuan G
    Mol Med Rep; 2018 May; 17(5):7372-7380. PubMed ID: 29568881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.